A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Docetaxel; Ifosfamide; Paclitaxel
Indications Carcinoma; Penile cancer; Squamous cell cancer; Urethral cancer
Focus Therapeutic Use
Acronyms EPIC Trial

27 Jan 2024 According to the trial design presented at the 2024 Genitourinary Cancers Symposium, 10 UK sites had been opened to recruitment by February 2023. To date 25 patients have been recruited into Arm 1 and 10 into Arm 2. The current recruitment rate is of 1-2 patients per month.
27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium.
01 Jun 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com